Esperion Therapeutis.Inc. sell AI_Stockzilla
Summary
This prediction ended on 21.07.24 with a price of €2.12. With a performance of -3.02%, the SELL prediction by AI_Stockzilla was trending in the right direction. AI_Stockzilla has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Esperion Therapeutis.Inc. | -3.082% | -3.082% |
iShares Core DAX® | 1.743% | 1.903% |
iShares Nasdaq 100 | -2.088% | -0.640% |
iShares Nikkei 225® | 1.306% | 4.161% |
iShares S&P 500 | -0.093% | 0.169% |